Neogen (NEOG) has drawn investor attention after its recent share price move, with the stock up about 24% over the past month and roughly 30% over the past 3 months.
Zooming out, Neogen’s 1 year total shareholder return of about 103% and year to date share price return of nearly 67% point to strong recent momentum. However, the 3 year and 5 year total shareholder returns, down roughly 50% and 74% respectively, highlight how this rebound follows a much weaker longer term record.
Capture Neogen’s sharp rebound in context by comparing it with a curated 19 high quality undiscovered gems that have been quietly rebuilding momentum after tough multi year stretches.Bulls point to Neogen’s sharp rebound and modest revenue and net income growth, while bears focus on the loss and weak multi year returns. Which case does the current valuation evidence lean toward next?
Most Popular Narrative: 10.3% Undervalued
Neogen's most followed valuation narrative points to a fair value of about $13 per share compared with the recent close at $11.66, which frames the current rebound in a different light. That gap is built on detailed assumptions about slower revenue growth, margin improvement and what investors may be willing to pay for those future earnings.
Operational improvements and automation at the new Petrifilm production facility, alongside targeted actions to reduce inefficiencies in sample collection and inventory management, are expected to drive gross margin and EBITDA margin improvements over the coming quarters as execution stabilizes and overhead absorption rates improve.
Read the complete narrative. Read the complete narrative.
Want to understand why this Neogen narrative still arrives at a higher fair value despite modest revenue assumptions? The key variables are future profit margins, the earnings level they imply and the valuation multiple that ties it all together.
Result: Fair Value of $13 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Neogen’s narrative still carries real execution risk, especially if 3M Food Safety integration issues linger or if tariffs and trade uncertainty continue to pressure margins.
Find out about the key risks to this Neogen narrative.
Next Steps
With sentiment on Neogen pulled between a sharp rebound and lingering concerns, it makes sense to review the data yourself and move quickly to form your own view using the 1 important warning sign.
Looking for more investment ideas beyond Neogen?
If you want a stronger watchlist around Neogen, do not stop at a single stock. Broader ideas can help you balance conviction with diversification and fresh opportunities.
- Target potential mispricings by scanning a curated 44 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
- Strengthen portfolio resilience by reviewing a list of solid balance sheet and fundamentals (51 results) so you focus on companies with healthier financial foundations.
- Reduce portfolio shocks by checking a 74 resilient stocks with low risk scores that may help smooth returns when individual stocks move sharply.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com